image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 11.4
-0.175 %
$ 13.6 B
Market Cap
-15.62
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one VTRS stock under the worst case scenario is HIDDEN Compared to the current market price of 11.4 USD, Viatris Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one VTRS stock under the base case scenario is HIDDEN Compared to the current market price of 11.4 USD, Viatris Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 31, 2025.

The intrinsic value of one VTRS stock under the best case scenario is HIDDEN Compared to the current market price of 11.4 USD, Viatris Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
15.4 B REVENUE
-5.14%
766 M OPERATING INCOME
-52.55%
54.7 M NET INCOME
-97.37%
2.8 B OPERATING CASH FLOW
-5.18%
-764 M INVESTING CASH FLOW
-50.25%
-2.3 B FINANCING CASH FLOW
40.64%
3.74 B REVENUE
-1.54%
226 M OPERATING INCOME
194.16%
94.8 M NET INCOME
129.04%
826 M OPERATING CASH FLOW
118.02%
1.75 B INVESTING CASH FLOW
365.11%
-1.64 B FINANCING CASH FLOW
-93.03%
Balance Sheet Viatris Inc.
image
Current Assets 13 B
Cash & Short-Term Investments 1.18 B
Receivables 4.04 B
Other Current Assets 7.75 B
Non-Current Assets 34.7 B
Long-Term Investments 1.14 B
PP&E 3.01 B
Other Non-Current Assets 30.6 B
Current Liabilities 7.78 B
Accounts Payable 1.38 B
Short-Term Debt 2.02 B
Other Current Liabilities 4.38 B
Non-Current Liabilities 19.4 B
Long-Term Debt 16.4 B
Other Non-Current Liabilities 3.09 B
EFFICIENCY
Earnings Waterfall Viatris Inc.
image
Revenue 15.4 B
Cost Of Revenue 8.99 B
Gross Profit 6.44 B
Operating Expenses 5.67 B
Operating Income 766 M
Other Expenses 712 M
Net Income 54.7 M
RATIOS
41.74% GROSS MARGIN
41.74%
4.97% OPERATING MARGIN
4.97%
0.35% NET MARGIN
0.35%
0.27% ROE
0.27%
0.11% ROA
0.11%
0.49% ROIC
0.49%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Viatris Inc.
image
Net Income 54.7 M
Depreciation & Amortization 2.74 B
Capital Expenditures -474 M
Stock-Based Compensation 181 M
Change in Working Capital -711 M
Others 431 M
Free Cash Flow 2.33 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Viatris Inc.
image
Wall Street analysts predict an average 1-year price target for VTRS of $13.3 , with forecasts ranging from a low of $10 to a high of $15 .
VTRS Lowest Price Target Wall Street Target
10 USD -12.28%
VTRS Average Price Target Wall Street Target
13.3 USD 16.54%
VTRS Highest Price Target Wall Street Target
15 USD 31.58%
4. DIVIDEND ANALYSIS
1.03% DIVIDEND YIELD
0.12 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Viatris Inc.
image
Sold
0-3 MONTHS
347 K USD 1
3-6 MONTHS
7.05 M USD 1
6-9 MONTHS
4.52 M USD 2
9-12 MONTHS
3.94 M USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Nov 11, 2024
Sell 347 K USD
Campbell Paul
See Remarks
- 26925
12.876 USD
1 year ago
Oct 26, 2023
Bought 171 USD
KORMAN HARRY
Director
+ 19
9.007 USD
2 years ago
Mar 16, 2022
Bought 2.49 K USD
KORMAN HARRY
Director
+ 238.76
10.421 USD
2 years ago
Mar 04, 2022
Bought 11.6 K USD
KORMAN HARRY
Director
+ 1150
10.079 USD
3 years ago
Dec 16, 2021
Bought 2.26 K USD
KORMAN HARRY
Director
+ 176.17
12.836 USD
3 years ago
Sep 16, 2021
Bought 2.24 K USD
KORMAN HARRY
Director
+ 162.44
13.811 USD
3 years ago
Jun 16, 2021
Bought 2.23 K USD
KORMAN HARRY
Director
+ 144.73
15.391 USD
3 years ago
Mar 09, 2021
Bought 4.86 K USD
KORMAN HARRY
Director
+ 349
13.939 USD
3 years ago
Feb 25, 2021
Bought 10.7 K USD
KORMAN HARRY
Director
+ 713
14.966 USD
4 years ago
Jan 15, 2021
Bought 14.2 K USD
KORMAN HARRY
Director
+ 837
16.993 USD
4 years ago
Dec 11, 2020
Bought 10.5 K USD
KORMAN HARRY
Director
+ 613
17.147 USD
4 months ago
Sep 12, 2024
Sell 1.63 M USD
Malik Rajiv
Director
- 139681
11.6563 USD
4 months ago
Sep 12, 2024
Sell 707 K USD
Malik Rajiv
Director
- 60319
11.7136 USD
5 months ago
Aug 28, 2024
Sell 595 K USD
Malik Rajiv
Director
- 50000
11.9015 USD
5 months ago
Aug 30, 2024
Sell 600 K USD
Malik Rajiv
Director
- 50000
12 USD
5 months ago
Aug 21, 2024
Sell 1.18 M USD
Malik Rajiv
Director
- 100000
11.7526 USD
5 months ago
Aug 22, 2024
Sell 1.17 M USD
Malik Rajiv
Director
- 100000
11.7263 USD
5 months ago
Aug 23, 2024
Sell 1.18 M USD
Malik Rajiv
Director
- 100000
11.751 USD
7 months ago
Jun 13, 2024
Sell 901 K USD
Malik Rajiv
Director
- 85660
10.5153 USD
7 months ago
Jun 14, 2024
Sell 2.69 M USD
Malik Rajiv
Director
- 264300
10.1789 USD
8 months ago
May 28, 2024
Sell 928 K USD
Roman Brian
Chief Legal Officer
- 89419
10.3829 USD
10 months ago
Mar 13, 2024
Sell 3.02 M USD
Mauro Anthony
See Remarks
- 250000
12.0948 USD
10 months ago
Mar 05, 2024
Sell 300 K USD
Campbell Paul
See Remarks
- 24353
12.33 USD
10 months ago
Mar 05, 2024
Sell 247 K USD
Lyons Dillon JoEllen
Director
- 20000
12.36 USD
10 months ago
Mar 04, 2024
Sell 223 K USD
Ni Xiangyang (Sean)
President, Greater China
- 17755
12.5394 USD
10 months ago
Mar 04, 2024
Sell 46.7 K USD
Ni Xiangyang (Sean)
President, Greater China
- 3777
12.3582 USD
11 months ago
Feb 23, 2024
Sell 54 K USD
Cuneo Andrew
See Remarks
- 4000
13.5 USD
11 months ago
Feb 15, 2024
Sell 50 K USD
Cuneo Andrew
See Remarks
- 4000
12.5 USD
1 year ago
Jan 04, 2024
Sell 46 K USD
Cuneo Andrew
See Remarks
- 4000
11.5 USD
1 year ago
Dec 14, 2023
Sell 42 K USD
Cuneo Andrew
See Remarks
- 4000
10.5 USD
1 year ago
Nov 24, 2023
Sell 140 K USD
Ni Xiangyang (Sean)
President, Greater China
- 14937
9.3688 USD
1 year ago
Mar 06, 2023
Sell 34.9 K USD
Ni Xiangyang (Sean)
President, Greater China
- 3148
11.0835 USD
1 year ago
Mar 03, 2023
Sell 34.6 K USD
Ni Xiangyang (Sean)
President, Greater China
- 3093
11.1798 USD
1 year ago
Feb 28, 2023
Sell 58.9 K USD
Ni Xiangyang (Sean)
President, Greater China
- 5250
11.2178 USD
2 years ago
Nov 25, 2022
Sell 140 K USD
Ni Xiangyang (Sean)
President, Greater China
- 12800
10.9547 USD
2 years ago
Aug 17, 2022
Sell 99.9 K USD
van der Meer Mohr Pauline
director:
- 9440
10.5839 USD
2 years ago
May 27, 2022
Sell 106 K USD
Taddese Menassie
See Remarks
- 8813
12.0737 USD
2 years ago
Mar 15, 2022
Bought 26.7 K USD
CORNWELL W DON
director:
+ 2700
9.8968 USD
2 years ago
Mar 15, 2022
Bought 497 K USD
GOETTLER MICHAEL
Chief Executive Officer
+ 50352
9.866 USD
2 years ago
Mar 09, 2022
Sell 2.52 M USD
COURY ROBERT J
Executive Chairman
- 250000
10.0731 USD
3 years ago
May 21, 2021
Bought 7.72 K USD
CORNWELL W DON
Director
+ 500
15.45 USD
3 years ago
May 19, 2021
Bought 23.7 K USD
CORNWELL W DON
Director
+ 1500
15.7933 USD
3 years ago
Mar 03, 2021
Bought 41.5 K USD
CORNWELL W DON
Director
+ 3000
13.8383 USD
4 years ago
Dec 16, 2020
Bought 490 K USD
KILTS JAMES M
Director
+ 27736
17.6555 USD
7. News
Is Viatris (VTRS) a Great Value Stock Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 2 weeks ago
Viatris Inc. (VTRS) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript) Viatris Inc. (NASDAQ:VTRS ) 43rd Annual J.P. Morgan Healthcare Conference 2025 January 14, 2025 11:15 AM ET Company Participants Scott Smith - CEO Doretta Mistras - CFO Philippe Martin - Chief R&D Officer Corinne Le Goff - Chief Commercial Officer Conference Call Participants Chris Schott - JPMorgan Doretta Mistras - CFO Chris Schott Good morning, everybody. seekingalpha.com - 2 weeks ago
Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference PITTSBURGH , Jan. 7, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025. prnewswire.com - 3 weeks ago
Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes We have rated Viatris in the "neutral/hold" category since 2021. Over this time, the stock has lagged Treasury bills, despite sporting a high double digit "free cash flow yield". We tell you why that has not worked till now and why we are getting ready to trade this. seekingalpha.com - 3 weeks ago
US FDA sends warning letter to Viatris over India manufacturing facility Viatris said on Monday it has received a warning letter from the U.S. Food and Drug Administration after an inspection at its oral finished dose manufacturing facility in Indore, India earlier this year. reuters.com - 1 month ago
Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology Biomarker data from CARE study characterizing cenerimod's mechanism of action in systemic lupus erythematosus also published in the Annals of the Rheumatic Diseases PITTSBURGH , Dec. 18, 2024 /PRNewswire/ --  Viatris Inc.  (NASDAQ: VTRS) today announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus erythematosus (SLE). The results, published in Lancet Rheumatologyi , showed cenerimod 4 mg demonstrated clinically meaningful and sustained improvement from baseline on multiple measures of SLE disease activity compared to placebo, in addition to stable background SLE therapy. prnewswire.com - 1 month ago
Mapi Pharma is Seeking New Depot Product Partnerships Management to Participate in 7th Annual Evercore HealthCONx Conference Management to Participate in 7th Annual Evercore HealthCONx Conference globenewswire.com - 1 month ago
2 Generic Drug Stocks Ready to Surge in 2025 Generic and biosimilar drugs are often preferred over the brand name version due to their cheaper prices. Generics are exact duplicates of the branded counterparts, while biosimilars are "similar" and often require clinical trials. marketbeat.com - 2 months ago
UK watchdog fines Viatris $1.9 mln over rule breach in Theramex probe Britain's competition watchdog fined U.S. firm Viatris 1.5 million pounds ($1.88 million) on Friday for violating an order during its investigation into Theramex's acquisition of European rights to two of Viatris's women's healthcare product ranges. reuters.com - 2 months ago
Viatris Inc. (VTRS) Management Presents at Jefferies London Healthcare Conference (Transcript) Viatris Inc. (NASDAQ:VTRS ) Jefferies London Healthcare Conference Transcript November 21, 2024 5:30 AM ET Company Participants Scott Smith - Chief Executive Officer Doretta Mistras - Chief Financial Officer Corinne Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Conference Call Participants Glen Santangelo - Jefferies Glen Santangelo All right. Good morning, everybody. seekingalpha.com - 2 months ago
Viatris Inc. (VTRS) UBS Global Healthcare Conference (Transcript) Viatris Inc. (NASDAQ:VTRS ) UBS Global Healthcare Conference November 12, 2024 11:45 AM ET Company Participants Doretta Mistras - CFO Conference Call Participants Ashwani Verma - UBS Ashwani Verma Good day, everybody. My name is Ash Verma, I cover SMID-cap, biotech and spec pharma at UBS, and welcome to UBS Global Healthcare Conference with us. seekingalpha.com - 2 months ago
Bargain Priced Viatris Reports Strong Q3 Earnings Results Bargain Priced Viatris Reports Strong Q3 Earnings Results seekingalpha.com - 2 months ago
8. Profile Summary

Viatris Inc. VTRS

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 13.6 B
Dividend Yield 1.03%
Description Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Contact 1000 Mylan Boulevard, Canonsburg, PA, 15317 https://www.viatris.com
IPO Date March 17, 1980
Employees 32000
Officers Mr. Derek Glover Chief Quality Officer Mr. Ramkumar V. Rayapureddy Chief Information Officer Ms. Theodora Mistras Chief Financial Officer Mr. Andrew Enrietti Chief People Officer Mr. Scott Andrew Smith Ph.D. Chief Executive Officer & Director Mr. Brian S. Roman Chief Legal Officer Mr. Paul B. Campbell Chief Accounting Officer, Senior Vice President & Corporate Controller Dr. Jeffrey Nau MMS, Ph.D. President of Viatris Eye Care Division Ms. Lara Ramsburg Chief Corporate Affairs Officer Mr. Menassie Taddese M.B.A. President of Emerging Markets